Frontlight ResearchEarly access
Taking peoplePhase 2/3
Fractional dose singles vaccination
Key facts
- Who runs it
- Leids Universitair Medisch Centrum (LUMC)
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 104 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 2 Feb 2027
- Type of study
- Interventional
- Record updated
- 28 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Aged between 50 and 85 years at the time of informed consent
- Capable of giving personal signed informed consent, which includes compliance with the requirements listed in this protocol
- Living in the Netherlands for over 30 years or a history of chickenpox
Who cannot take part
- Previous vaccination against Herpes Zoster or chickenpox
- Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation
- Receipt of any other non-study vaccine within 28 days, before first study dose
- Anticipated receipt of any other non-study vaccine within 28 days, after last study dose administration
- Receipt of systemic or topical corticosteroids
- Women who are pregnant or breastfeeding. A urine pregnancy test will be performed in women under 53 years of age who have menstruated within the previous 12 months
- History of Herpes Zoster in the last 5 years before inclusion
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
- Individuals with a history of autoimmune disease or an active autoimmune disease requir-ing therapeutic intervention
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opin-ion of the investigator, contraindicate intramuscular injection
- A medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participa-tion or, in the investigator#s judgment, make the participant inappropriate for the study
- Immunosuppressed individuals with known or suspected immunodeficiency, as determined by history
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine non-inferiority of the antibody response against VZV four weeks after the vaccination of the intradermal fractional dose compared to the full dose.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- SHING-ID: Fractional dose shingles vaccination
- Record updated
- 28 September 2026